¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"color flow imaging"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • chemical shift imaging
    È­Çк¯À§¿µ»ó
  • dynamic imaging
    ¿ªµ¿¿µ»ó, µ¿¿µ»ó
  • diffusion tensor imaging
    È®»êÅÙ¼­¿µ»ó
  • diffusion weighted imaging
    È®»ê°­Á¶¿µ»ó
  • fast imaging technique
    °í¼Ó¿µ»ó±â¹ý
  • frequency modulation imaging
    Á֯ļöº¯Á¶¿µ»ó
  • functional magnetic resonance imaging
    ±â´ÉÀÚ±â°ø¸í¿µ»ó¹ý
  • gradient acquisition imaging
    ±â¿ï±âȹµæ¿µ»ó
  • gradient echo imaging
    ±â¿ï±â¿¡ÄÚ¿µ»ó
  • gradient refocused imaging
    ±â¿ï±âÀçÃÊÁ¡¿µ»ó
  • hybrid imaging
    È¥ÇÕ¿µ»ó
  • intravoxel coherent motion imaging
    È­Àû¼Ò³»°áÁý¿îµ¿¿µ»ó
  • intravoxel incoherent motion imaging
    È­Àû¼Ò³»ºñ°áÁý¿îµ¿¿µ»ó
  • imaging
    1. ¿µ»ó, Á¶¿µ 2. ¿µ»óÈ­, ¿µ»ó¹ý 3. »ó»ó
  • imaging gradient
    ¿µ»ó±â¿ï±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • velocity imaging
    ¼Óµµ¿µ»ó
  • color adaptation
    »öÀûÀÀ
  • color agnosia
    »öäÀνĺҴÉÁõ
  • color amblyopia
    »ö¾à
  • color anomaly
    »ö°¢ÀÌ»ó
  • color blindness
    »ö¸Í
  • total color blindness
    ¿ÏÀü»ö°¢»ó½Ç, ¿ÏÀü»ö¸Í
  • color
    »ö
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • color circle
    »ö»ó¿ø
  • color contrast
    »ö´ëºñ, »ö´ëÁ¶
  • color discrimination
    »öºÐº°, »öäºÐº°
  • color mapping
    »öÁöµµÈ­
  • color matching
    »ö¦Áþ±â
  • color perimetry
    »ö½Ã¾ßÃøÁ¤(¹ý)
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • imaging procedure
    ¿µ»ó ÀýÂ÷
  • imaging sequence
    ¿µ»ó ¿¬¼â
  • phase offset multiplannar (POMP) imaging
    À§»ó ¿ÀÇÁ¼Â ´Ù¸é ¿µ»ó
  • radionuclide imaging
    ¹æ»ç¼º ÇÙÁ¾À̸ÞÀÌ¡.
  • real time imaging
    ½Ç½Ã°£ ¿µ»ó ±â¹ý
  • receptor imaging
    ¼ö¿ëü¿µ»ó(È­)
  • ELBF=£¾effective liver blood flow
    À¯È¿¼º °£Ç÷·ù.
  • ELBF=£¾effective liver blood flow
    À¯È¿ °£Ç÷·ù.
  • ERPF => effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
  • ERPF=£¾effective renal plasma flow
    À¯È¿½ÅÇ÷·ù·®.
  • Flow
    À¯·®(êüÕá), È帧
  • Flow-limited exchange
    À¯·®Á¦Çѱ³È¯(ð¤ùÚÎßüµ)
  • High intensity proton flow
    °í°­µµ ¾çÀÚ À¯µ¿
  • Pulsatile flow
    ¹Úµ¿ Ç÷·ù (ÚÑÔÑ úì×µ)
  • RPF => renal plasma flow
    ½ÅÇ÷Àå·ù(·®)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • color pixel
    »ö È­¼Ò
  • color reaction
    ¹ß»ö¹ÝÀÀ(Û¡ßäÚãëë), »öä¹ÝÀÀ(ßäóôÚãëë).
  • color rivalry
    »ö°æÇÕ
  • color valency
    »ö°ª, »ö°¡
  • color vision
    »öÁ¶°¨°¢
  • color vision
    »ö°¢.
  • color vision deficiency
    »ö°¢ÀÌ»ó
  • color= colo(u)r
    »ö(ßä), »öä(ßäóô), °¡½Ã±¤¼±(ʦãÊÎÃàÊ), ¿°·á(æøè÷).
  • complementary color
    º¸»ö
  • congenital color vision defect
    ¼±Ãµ»ö°¢ÀÌ»ó
  • coupling color
    Ä¿Çøµ¿°·á.
  • difference color
    Â÷»ö(̤Ë×).
  • functional color blindness
    ±â´É¼º»ö¸Í
  • gingival color
    Ä¡Àº»ö.
  • mixed color
    È¥ÇÕ»ö(ûèùêßä).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • in-flow effect
    À¯ÀÔ È¿°ú
  • in-plane flow misregistration
    Æò¸é³»À¯µ¿¿Àµî·Ï
  • laminar flow
    Ãþ·ù
  • liver blood flow
    °£ÀåÇ÷¾×À¯Åë, °£Ç÷·ù
  • low intensity void in proton flow
    ¾ç¼ºÀÚÈ帧ÀÇ Àú°­µµ¼Ò½Ç
  • parabolic flow
    Æ÷¹°¼±ÇüÀ¯Ã¼È帧
  • plug flow
    Àü·ù
  • proton flow
    ¾çÀÚÀ¯µ¿
  • proton flow abnormality
    ¾çÀÚÀ¯µ¿ÀÌ»ó
  • proton flow deficit
    ¾çÀÚÀ¯µ¿°áÇÌ
  • pseudodiastole in high intensity proton flow
    °í°­µµ¾çÀÚÀ¯µ¿¿¡¼­ À§À̿ϱâ
  • quantitative flow measurement
    Á¤·®ÀûÀ¯·®ÃøÁ¤
  • turbulent flow
    ¿Í·ù, ³­·ù
  • adjunctive imaging technique
    º¸Á¶¿µ»ó±â¹ý
  • advanced Fourier imaging
    Áøº¸Fourier¿µ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EHBF estimated hepatic blood flow; exercise hyperemia blood flow; extrahepatic blood flow
MBF medullary blood flow; muscle blood flow; myocardial blood flow
PBF peripheral blod flow; placental blood flow; pulmonary blood flow
ABCD airway, breathing, circulation, differential diagnosis (or defibrillate) [in cardiopulmonary resusci...
BCA balloon catheter angioplasty; bicinchoninic acid; blood color analyzer; Blue Cross Association; bran...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CDU Color-Doppler ultrasonography
CCDS Color-coded Doppler sonography
TCCS Transcranial color-coded Duplex sonography
TCCD Transcranial color-coded duplex sonography
TCCS Transcranial color-coded real-time sonography
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ultrasonic imaging
    ÃÊÀ½ÆÄ ¿µ»ó
  • Zebra-stripe imaging method
    ¾ó·è¸» ¹«´Ì ¿µ»ó ¹æ¹ý
  • air flow
    ±â·ù
  • aqueous flow
    ¹æ¼ö È帧, ¹æ¼ö·ù
  • blood flow pattern
    Ç÷·ù ¾ç»ó
  • blood flow velocity
    Ç÷·ù ¼Óµµ
  • bulk flow
    µ¢¾î¸® È帧
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • coronary blood flow
    °üÇ÷·ù, °ü»ó Ç÷·ù
  • counter current flow
    ¿ªÈ帧, °Å²Ù·Î È帧, ¿ª·ù
  • counter flow
    ´ëÇâ·ù, ¿ª·ù, ¹Ý·ù
  • flow amount
    À¯·®
  • flow compensated pulse sequence
    À¯µ¿ º¸»ó ÆÞ½º ¿¬¼â
  • flow compensation gradient technique
    À¯µ¿ º¸»ó °æ»ç ±â¹ý
  • flow cytometry
    À¯¼Ó ¼¼Æ÷ ºÐ¼®¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
through transfer imaging The production of an ultrasound image by detection and analysis of sound on the opposite side of the body from the emitting transducer.
Synonym: through transfer imaging.
(05 Mar 2000)
thyroid imaging <radiology> Tc-99m pertechnetate 6 mCi, I-123 sodium iodide 200 - 400 uCi PO
(12 Dec 1998)
transfer imaging The production of an ultrasound image by detection and analysis of sound on the opposite side of the body from the emitting transducer.
Synonym: through transfer imaging.
(05 Mar 2000)
ultrasound imaging <investigation, procedure> A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer.
(12 May 1997)
kidney: gallium imaging <radiology> 10-20% of Ga-67 excreted via GU tract; no renal activity after 24hrs abnormal uptake (images at 48-72 hrs): tumour, primary renal tumour (variable uptake), lymphoma/leukaemia, metastases (e.g., melanoma), inflammation, acute pyelonephritis (88% sensitivity); abscess, lobar nephroma, others, collagen vascular disease, vasculitis, Wegener granulomatosis, amyloidosis, haemochromatosis, hepatic failure, antineoplastic drugs, transplant rejection: acute, chronic, ATN see also: gallium: indications
(12 Dec 1998)
liver metastases: ultrasound imaging <radiology> Echogenic (25%), colonic carcinoma, hepatocellular carcinoma, treated breast carcinoma mixed echogenicity (37.5%), breast carcinoma, rectal carcinoma, lung carcinoma, stomach carcinoma, anaplastic cancer, cervical carcinoma, carcinoid hypoechoic (37.5%), lymphoma, pancreatic carcinoma, cervical carcinoma, lung carcinoma (adenocarcinoma), nasopharyngeal carcinoma see: liver metastases
(12 Dec 1998)
lung: gallium imaging <radiology> Scans at 48 hrs because 50% of normals show activity at 24 hrs, focal uptake, primary pulmonary malignancy, benign disorder: granuloma, abscess, pneumonia, silicosis, multifocal/diffuse uptake, infection, TB: active lesion, miliary TB, rapidly progressive TB pneumonia, PCP: unimpressive symptoms and CXR, CMV, inflammation: sarcoid, interstitial lung disease (pneumoconiosis, idiopathic pulmonary fibrosis, lymphangitic carcinomatosis), radiation pneumonitis, drugs: bleomycin, amiodarone, contrast lymphangiography (in 50%) see: gallium: indications, uptake with normal chest film
(12 Dec 1998)
average flow rate <physiology> The flow rate determined by dividing the total volume passed in a time period divided by the time period, usually quoted in mls per minute.
(05 Mar 2000)
Bingham flow The flow characteristics exhibited by a Bingham plastic.
(05 Mar 2000)
blood flow velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed.
(12 Dec 1998)
gene flow The movement of genes from one population to another viainterbreeding.
(09 Oct 1997)
maximal expiratory flow rate <chest medicine, physiology> Measurement of rate of airflow during the first liter expired after the first 200 ml have been exhausted during a forced vital capacity determination. Common abbreviations are MEFR, FEF 202-1200, and fef 0.2-1.2.
Acronym: MEFR
(21 Jun 2000)
maximal expiratory flow-volume curve <chest medicine> Curves depicting maximal expiratory flow in liters/second at each point of lung inflation (expressed in liters or percentage of forced vital capacity) during a forced vital capacity determination. Common abbreviation is mefv.
(12 Dec 1998)
maximal midexpiratory flow rate Measurement of rate of airflow over the middle half of a forced vital capacity determination (from the 25 percent level to the 75 percent level). Common abbreviations are mmfr and fef 25%-75%.
(12 Dec 1998)
renal blood flow, effective The amount of blood flowing to the parts of the kidney that are involved with the production of constituents of urine. It is that portion of the total renal blood flow that perfuses functional renal tissue (e.g., the glomeruli). It should be differentiated from renal plasma flow, effective which is based on the amount of plasma rather than on total renal blood.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • color prejudice
    À¯»öÀÎÁ¾(ÈæÀÎ)¿¡ ´ëÇÑ
  • color print
    ¿ø»ö ÆÇÈ­;õ¿¬»ö ÀÎÈ­
  • color printing
    ¿ø»ö Àμâ;Ä÷¯ÀÎÈ­
  • color scheme
    (½Ç³» Àå½Ä.º¹½Ä µîÀÇ)»öäÀÇ ¹èÇÕ(¼³°è)
  • color separation
    »öºÐÇØ
  • color sergeant
    ±º±â È£À§ ÇÏ»ç°ü
  • color signal
    »ö½ÅÈ£
  • color supplement
    (½Å¹® µîÀÇ)Ä÷¯ÆÇ ºÎ·Ï
  • color television (TV)
    Ä÷¯ ÅÚ·¹ºñÀü ¹æ¼Û(¼ö»ó±â)
  • color temperature
    »ö¿Âµµ
  • color wash
    ¼ö¼º ÆäÀÎÆ®
  • color-bearer
    (±º´ëÀÇ)±â¼ö
  • color-blind
    »ö¸ÍÀÇ;ÀÎÁ¾ Â÷º°À» ÇÏÁö ¾Ê´Â
  • color-breed
    ƯÁ¤ÇÑ »öÀ» ³»µµ·Ï(ǰÁ¾À»)°³·®ÇÏ´Ù
  • color-code
    (Àü¼±.¼öµµ µîÀ»)(¾Ë±â ½±°Ô)»öÄ¥ÇÏ¿© ±¸ºÐÇÏ´Ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á